- Home
- Results news
- Shree Ganesh Biotech
- Q2 FY27 results
Shree Ganesh Biotech Q2 FY27 results: net loss of ₹0.08 crore vs ₹0.01 crore profit, revenue down 79.2%
Shree Ganesh Biotech (India) Ltd reported standalone revenue of ₹0.16 crore in Q2 FY27, down from ₹0.77 crore in Q2 FY26, while EBITDA was unchanged at ₹0.40 crore. The company reported a net loss of ₹0.08 crore and basic EPS of ₹0.00 for the quarter.
Key points
- Q2 FY27 standalone revenue was ₹0.16 crore, down 79.2% from ₹0.77 crore in Q2 FY26.
- The company reported a net loss of ₹0.08 crore in Q2 FY27, against a net profit of ₹0.01 crore in Q2 FY26.
- EBITDA was ₹0.40 crore, unchanged from Q2 FY26, while the EBITDA margin was -252.2% compared with -51.6%.
- Basic EPS was ₹0.00 in Q2 FY27 and ₹0.00 in Q2 FY26.
- H1 FY27 revenue was ₹1.59 crore, down 26.0% from ₹2.15 crore in H1 FY26, with a net loss of ₹0.65 crore.
How did Shree Ganesh Biotech perform in Q2 FY27?
Shree Ganesh Biotech reported standalone revenue of ₹0.16 crore in Q2 FY27, down 79.2% from ₹0.77 crore in Q2 FY26 and down 88.8% from ₹1.43 crore in Q1 FY27. Other income was ₹0.32 crore, taking total income to ₹0.48 crore, against ₹1.18 crore in Q2 FY26 and ₹1.75 crore in Q1 FY27.
Total expenses were ₹0.56 crore, down 51.7% from ₹1.16 crore in Q2 FY26 and 75.9% from ₹2.32 crore in Q1 FY27. EBITDA was ₹0.40 crore, unchanged from Q2 FY26 and higher than ₹0.89 crore in Q1 FY27, while the EBITDA margin was -252.2% against -51.6% and -62.5%, respectively.
The company reported a net loss of ₹0.08 crore in Q2 FY27, compared with a net profit of ₹0.01 crore in Q2 FY26 and a net loss of ₹0.57 crore in Q1 FY27. Basic EPS was ₹0.00 in Q2 FY27, compared with ₹0.00 in Q2 FY26 and ₹0.01 in Q1 FY27. The results were standalone; no consolidated figures were provided.
| ₹ crore | Q2 FY27 | Q1 FY27 | Q2 FY26 | YoY | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 0.16 | 1.43 | 0.77 | −79.2% | −88.8% |
| Other income | 0.32 | 0.32 | 0.41 | −22.0% | +0.0% |
| Total expenses | 0.56 | 2.32 | 1.16 | −51.7% | −75.9% |
| EBITDA | −0.40 | −0.89 | −0.40 | ||
| EBITDA margin | -252.2% | -62.5% | -51.6% | −200.6 pp | −189.7 pp |
| Profit before tax | −0.08 | −0.57 | 0.01 | turned to loss | |
| Tax | 0 | 0 | 0 | ||
| Net profit | −0.08 | −0.57 | 0.01 | turned to loss | |
| EPS (₹) | 0.00 | −0.01 | 0.00 | turned to profit |
EBITDA here is revenue from operations less operating costs (total expenses excluding finance costs and depreciation): before other income and exceptional items. Growth is shown only when both figures are positive. Source: Company's results filing (XBRL).
What changed in Shree Ganesh Biotech's costs and profit?
Against Q2 FY26, cost of materials consumed fell by ₹0.84 crore to ₹0.28 crore, while employee benefit expense rose by ₹0.01 crore to ₹0.04 crore. Other expenses increased by ₹0.23 crore to ₹0.24 crore, and other income declined by ₹0.09 crore to ₹0.32 crore. Total expenses fell by ₹0.60 crore to ₹0.56 crore.
There was no exceptional item in Q2 FY27, and tax expense was ₹0 crore. Finance costs and depreciation were also ₹0 crore. The filing did not state a reason for the changes in revenue, costs, other income or the movement from a net profit of ₹0.01 crore in Q2 FY26 to a net loss of ₹0.08 crore.
| ₹ crore | Q2 FY27 | Q2 FY26 | Change | Change % |
|---|---|---|---|---|
| Cost of materials | 0.28 | 1.12 | −0.84 | −75.0% |
| Employee cost | 0.04 | 0.03 | +0.01 | +33.3% |
| Finance costs | 0 | 0 | 0 | |
| Depreciation | 0 | 0 | 0 | |
| Other expenses | 0.24 | 0.01 | +0.23 | +2300.0% |
| Total expenses | 0.56 | 1.16 | −0.60 | −51.7% |
| Other income | 0.32 | 0.41 | −0.09 | −22.0% |
| Tax | 0 | 0 | 0 |
Source: Company's results filing (XBRL).
How did the first half of FY27 go?
For H1 FY27, standalone revenue was ₹1.59 crore, down 26.0% from ₹2.15 crore in H1 FY26. Total income fell 25.2% to ₹2.23 crore from ₹2.98 crore, while the company moved from profit before tax of ₹0.34 crore to a loss of ₹0.65 crore.
Net profit attributable for H1 FY26 became a net loss of ₹0.65 crore in H1 FY27. Basic EPS was ₹0.02 in H1 FY27, against ₹0.01 in H1 FY26. The half-year figures shown in the filing are standalone.
| ₹ crore | H1 FY27 | H1 FY26 | Change |
|---|---|---|---|
| Revenue from operations | 1.59 | 2.15 | −26.0% |
| Profit before tax | −0.65 | 0.34 | turned to loss |
| Net profit | −0.65 | 0.34 | turned to loss |
| EPS (₹) | −0.02 | 0.01 |
Source: Company's results filing (XBRL).
What do the balance sheet and cash flow show?
Total assets increased to ₹74.12 crore at 30 September 2026 from ₹63.8 crore at 31 March 2026, while total equity was ₹62.98 crore against ₹63.63 crore. Borrowings rose to ₹11.0 crore from ₹0 crore, and cash was ₹0.01 crore at both dates. Inventories increased to ₹22.82 crore from ₹11.73 crore; trade receivables and trade payables were ₹0 crore at both dates.
For H1 FY27, net cash flow from operating activities was an outflow of ₹11.62 crore, compared with an outflow of ₹0.68 crore in H1 FY26. Investing cash flow was ₹0.62 crore against an outflow of ₹0.69 crore, while financing cash flow was ₹11.0 crore against ₹1.43 crore. Capital expenditure was ₹0 crore in both periods.
| ₹ crore | As of 30 September 2026 | As of 31 March 2026 |
|---|---|---|
| Total assets | 74.12 | 63.80 |
| Total equity | 62.98 | 63.63 |
| Borrowings | 11 | 0 |
| Cash and equivalents | 0.01 | 0.01 |
| Inventories | 22.82 | 11.73 |
| Trade receivables | 0 | 0 |
Source: Company's results filing (XBRL).
| ₹ crore | H1 FY27 | H1 FY26 |
|---|---|---|
| Cash from operations | −11.62 | −0.68 |
| Cash from investing | 0.62 | −0.69 |
| Cash from financing | 11 | 1.43 |
| Capital expenditure | 0 | 0 |
Source: Company's results filing (XBRL).
How has Shree Ganesh Biotech done over the last 8 quarters?
Revenue peaked at ₹14.41 crore in Q3 FY25 and bottomed at ₹0.16 crore in Q2 FY27. After reaching ₹0.70 crore in Q3 FY26, revenue rose to ₹2.12 crore in Q4 FY26, then fell to ₹1.43 crore in Q1 FY27 and ₹0.16 crore in Q2 FY27.
Profit was highest at ₹0.77 crore in Q3 FY25 and bottomed at a net loss of ₹0.95 crore in Q4 FY25. It moved to a net loss of ₹0.15 crore in Q4 FY26 and a net loss of ₹0.57 crore in Q1 FY27, before the loss narrowed to ₹0.08 crore in Q2 FY27. The EBITDA margin bottomed at -252.2% in Q2 FY27, compared with a peak of 3.2% in Q3 FY25.
How did Shree Ganesh Biotech shares react?
The filing appeared after market hours. The stock was down 2.2% five minutes after publication, unchanged at 15 and 30 minutes, and ended the reaction day up 2.2% from its pre-results close. By the next day's close, it was down 2.2% from that close; no five-day move was available.
On the reaction day, the biotechnology industry's median move was -0.2%, while the stock's excess move was 2.4 percentage points. By the next day's close, the industry median was up 5.9% and the stock's excess move was -8.1 percentage points. Earlier reaction-day moves included 0.0% on 4 August 2026, 3.3% on 14 May 2026 and -2.7% on 8 November 2025.
| After the filing | Stock | Biotechnology median |
|---|---|---|
| 5 minutes | −2.2% | |
| 15 minutes | +0.0% | |
| 30 minutes | +0.0% | |
| Reaction day | +2.2% | −0.2% |
| Next day | −2.2% | +5.9% |
Minutes are measured from the price when the filing appeared; days from the previous close. Source: MarketPing price-reaction measurement.
| Results filed on | Stock on the reaction day |
|---|---|
| 4 August 2026 | +0.0% |
| 14 May 2026 | +3.3% |
| 29 January 2026 | +1.6% |
| 8 November 2025 | −2.7% |
| 25 July 2025 | +0.0% |
| 22 May 2025 | −1.1% |
| 23 October 2024 | −1.0% |
| 13 August 2024 | −1.7% |
Source: MarketPing price-reaction measurement.
Quick answers
What was Shree Ganesh Biotech's revenue in Q2 FY27?
Revenue from operations was ₹0.16 crore, down 79.2% from ₹0.77 crore in Q2 FY26 (standalone).
Did Shree Ganesh Biotech make a profit in Q2 FY27?
No. It reported a net loss of ₹0.08 crore, against a net profit of ₹0.01 crore in Q2 FY26.
What was Shree Ganesh Biotech's EPS in Q2 FY27?
Basic earnings per share were ₹0.00, against ₹0.00 in Q2 FY26.
How did Shree Ganesh Biotech shares react to the Q2 FY27 results?
On the reaction day the stock moved +2.2% from the previous close; the median Biotechnology stock moved −0.2%.
When did Shree Ganesh Biotech announce its Q2 FY27 results?
On 2 November 2026, in a filing to the BSE.
Sources
- Board Meeting Intimation for Compliance Of Regulation 29 Of SEBI (LODR) Regulations, 2015 - Intimation Of Board Meeting. (BSE, 23 October 2026) · PDF
- Board Meeting Outcome for Outcome Of Board Meeting Held On 02Nd November 2026. (BSE, 2 November 2026) · PDF
- Regulation 33 Read With Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ("Listing Regulations") (BSE, 2 November 2026) · PDF
How this was written: every figure in the tables and charts is calculated from the company’s filed results (XBRL) and MarketPing’s price measurements. The text is drafted with AI from those figures and the filings, and a checker removes any sentence carrying a number it cannot trace to them. How we write these.
This is information, not investment advice. MarketPing does not recommend buying or selling any security.